Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine by Nanda, Kavinderjit & Moss, Alan C.
 
Update on the management of ulcerative colitis: treatment and
maintenance approaches focused on MMX® mesalamine
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Nanda, Kavinderjit, and Alan C Moss. 2012. Update on the
management of ulcerative colitis: treatment and maintenance
approaches focused on MMX® mesalamine. Clinical
Pharmacology : Advances and Applications 4: 41-50.
Published Version doi:10.2147/CPAA.S26556
Accessed February 19, 2015 10:49:15 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10466002
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA© 2012 Nanda and Moss, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Pharmacology: Advances and Applications 2012:4 41–50
Clinical Pharmacology: Advances and Applications
Update on the management of ulcerative colitis: 
treatment and maintenance approaches focused 
on MMX® mesalamine
Kavinderjit Nanda
Alan C Moss
Center for Inflammatory Bowel 
Disease, BIDMC/Harvard Medical 
School, Boston, MA, USA
Correspondence: Alan C Moss 
BIDMC, 330 Brookline Ave, Boston,  
MA 02215, USA 
Tel +1 617 667 3197 
Fax +1 617 667 1171 
Email amoss@bidmc.harvard.edu
Abstract: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically 
manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer 
and extraintestinal manifestations, may also develop. The goals of management are to induce 
and maintain clinical remission and to screen for complications of this disease. Mesalamine is 
a 5-aminosalicylic acid compound that is the first-line therapy to induce and maintain clinical 
remission in patients with mild-to-moderate UC. For patients who are refractory to mesalamine 
or have more severe disease, steroids, azathioprine/mercaptopurine, cyclosporine, or infliximab 
may be used, induce and/or maintain remission. The various formulations of mesalamine avail-
able are primarily differentiated by the methods of delivery of the active compound of the drug 
to the colon. Mesalamine with Multi-Matrix System® (MMX) technology (Cosmo SpA, Milan, 
Italy) is an oral (1.2 g), once-daily tablet formulation of mesalamine used for the treatment of 
UC (Lialda® or Mezavant®, Shire Pharmaceuticals Inc, Wayne, PA). In clinical studies, MMX 
mesalamine (taken as a once-daily dose of 2.4 or 4.8 g) effectively induced and maintained 
clinical remission in patients with active mild-to-moderate UC. The overall safety profile of 
MMX mesalamine is similar to other oral mesalamine formulations. The use of such once-daily 
formulations has led to intense interest in whether simplified pill regimens can improve patient 
adherence to mesalamine therapy.
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Ulcerative colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract of 
unknown etiology. UC is characterized by recurring episodes of inflammation limited 
to the mucosal and submucosal layer of the colon. It invariably involves the rectum 
and may extend in a proximal and continuous fashion to involve other portions of the 
colon.1 The onset and relapse of the disease may be triggered by environmental factors 
that transiently break the mucosal barrier, stimulate immune responses, or alter the 
balance between beneficial and pathogenic enteric bacteria.2 Patients with UC follow 
a relapsing and remitting clinical course, with symptoms of bloody diarrhea, rectal 
urgency, and abdominal pain during disease activity.3 In addition, patients may suffer 
from extraintestinal manifestations of UC, including episcleritis, scleritis, uveitis, 
peripheral arthropathies of small and large joints, erythema nodosum, pyoderma 
gangrenosum, axial arthropathies, sacroiliitis, ankylosing spondylitis, and primary 
sclerosing cholangitis.4 There is an increased risk for colorectal cancer (CRC) with 
longstanding inflammation, with risks reported at 0.5%–1% per year.5 These incidence 
rates corresponded to cumulative probabilities of 2% by 10 years, 8% by 20 years, 
and 18% by 30 years.6
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Ulcerative colitis most commonly affects teenagers and 
young adults (onset between ages 15 and 40 years), but can 
occur in any age group. Breakdown by racial and ethnic 
subgroups indicate that higher rates of inflammatory bowel 
disease (IBD) occur in people of Caucasian and Ashkenazi 
Jewish origin than in individuals of other backgrounds.7 It has 
a prevalence of 238 per 100,000 (95% confidence intervals 
[CI]: 234–241) in the United States adult population and an 
incidence rate of 2.2 to 14.3 cases per 100,000 person-years 
in North America.8 Although the incidence rates of UC 
increased after 1940, they have remained stable over the past 
30 years.1 Since 1991, the prevalence of UC has decreased 
by 7%.1 The rates are highest in northern climates and in 
well-developed areas of the world, such as North America, 
Great Britain, and Scandinavia, and lowest in southern cli-
mates and in underdeveloped areas.9 The disease has become 
more common in the developing world as different countries 
adopt Western lifestyles.8 Studies of migrant populations and 
populations of developing countries demonstrated a recent, 
slow increase in the incidence of UC.10 Such epidemiologic 
observations indicated that there are strong environmental 
influences on IBD, which is supported by the relatively low 
concordance rate of 10% in identical twins.11 Differences in 
incidence across age, time, and geographic region suggest 
that environmental factors significantly modify the expres-
sion of UC. The strongest protective environmental factors 
identified are cigarette smoking and appendectomy.8 Former 
smokers are approximately 1.7 times more likely to develop 
the disease than those who have never smoked. Whether other 
factors, such as diet, oral contraceptives, perinatal/childhood 
infections, or atypical mycobacterial infections, play a role in 
expression of inflammatory bowel disease remains unclear.
Current management of ulcerative 
colitis
The goal of managing patients with UC is to induce and 
maintain clinical and endoscopic remission and to prevent 
or treat complications. The majority of patients are success-
fully   managed with pharmacologic therapies, but surgical 
resection of the colon (colectomy) may be needed for 
refractory disease or complications, such as strictures or 
carcinoma.   Conventional medical therapies for UC include 
5-  aminosalicylic acid (5-ASA), corticosteroids, thiopu-
rines, and anti-tumor necrosis factor (TNF) agents.12 The 
initial therapeutic approach depends upon both the extent 
of colonic involvement and the severity of the disease pro-
cess at presentation. Medical management usually involves 
a “step-up” approach, starting with topical or oral agents 
and progressing to more complex agents, with risk of more 
serious adverse effects, in those who do not respond to first-
line agents.3 Since there is no known cure for UC (except a 
colectomy), most patients take lifelong maintenance medical 
therapy to prevent disease relapse.
Medical therapy involves agents used to achieve clinical 
response and remission (induction agents) and those used to 
maintain clinical remission (maintenance agents), although 
many drugs can be used for both situations. In patients with 
“distal” disease (rectum and sigmoid colon), topical therapy 
is the preferred choice of treatment. Suppositories are effec-
tive in the rectosigmoid area, whereas enemas can reach 
the splenic flexure. For active distal disease, the American 
College of Gastroenterology (ACG) Practice Guidelines rec-
ommend topical therapy with mesalamine, hydrocortisone, 
or budesonide.3 Topical mesalamine agents are superior to 
topical steroids or oral aminosalicylates in this setting.13 
A systematic review of topical 5-ASA has confirmed the 
efficacy of rectal-5-ASA in inducing remission and that it is 
superior to rectal corticosteroids or placebo.14 Several meta-
analyses have concluded that rectal 5-ASA was superior 
to placebo for inducing remission and for maintenance of 
remission.15–17
Oral mesalamine or sulfasalazine are 5-ASAs that are 
usually required in patients with disease extending beyond 
the sigmoid colon. The ACG recommends that patients 
with mild to moderate active extensive colitis should begin 
therapy with oral sulfasalazine or mesalamine in doses up to 
4.8 g per day.3 In a series of meta-analyses by Sutherland and 
colleagues18,19 and Ford et al,20 oral 5-ASAs were shown to 
be more effective than placebo in induction and maintenance 
of remission in UC. Efficacy rates reported for all 5-ASA 
agents are similar, although few comparative studies have 
been performed. One RCT reported no difference between 
similar doses of pH-dependent release and timed-release 
mesalamine formulations in induction of remission of active 
UC.21 There appears to be a dose-dependent effect with 
mesalamine, as doses . 2 g/day were found to have better 
  efficacy compared to ,2 g/day in induction and   maintenance.20 
Although multiple daily doses have been used in initial trials 
for induction of remission, a once-daily dose of mesala-
mine is as effective as conventional dosing schedules for 
the maintenance of remission in UC.22–24 Clinical response 
rates of 60%–70% and clinical remission rates of 40%–70% 
have been reported in various studies from 6 to 8 weeks.18,20 
Meta-analyses of these induction studies concluded that the 
mean remission rate with mesalamine was 42%, compared 
with 24% in placebo-treated patients.20
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Once clinical remission has been achieved, mesalamine 
suppositories or enemas are recommended for maintenance of 
remission in patients with distal disease and oral mesalamine 
is recommended for those with more extensive disease.12 
Maintenance of remission rates of 61%–68% at 12 months 
with oral mesalamine has been reported.25,26 A meta-analysis 
by Ford et al reported that 42% of prescribed patients relapsed 
compared with 65% of patients taking placebo after 6 to 
12 months of therapy.20 Combined oral and rectal 5-ASA 
therapy appeared superior to oral 5-ASAs for the induction of 
remission of mildly to moderately active left-sided UC, and 
intermittent topical 5-ASAs appeared superior to oral 5-ASAs 
for preventing relapse of quiescent left-sided UC.16
The US Food and Drug Administration (FDA)-approved 
oral doses for induction of remission are as follows: Asacol® 
(Warner Chilcott Company, Dublin, Ireland) 800 g three 
times daily, Asacol HD 1.6 g three times daily, and Pentasa® 
  (Shire, Wayne, PA) 4 g daily. The US FDA-approved doses 
for maintaining remission are as   follows: Asacol 1.6 g 
daily in divided doses, Pentasa 4 g daily, and Apriso® (Salix 
Pharmaceuticals, Morrisville, NC) 1.5 g daily. The recom-
mended dosage of Multi-Matrix System® (MMX; Cosmo 
SpA, Milan, Italy) mesalamine (Lialda®; Shire Pharma-
ceuticals Inc, Wayne, PA) is 2.4 g or 4.8 g once daily for 
up to 8 weeks as induction therapy and 2.4 g once daily as 
maintenance therapy.
Data from ASCEND 1 and 2 trials with oral mesalamine 
(Asacol) reported that times to resolution and improvement 
of both rectal bleeding and stool frequency were shorter 
with 4.8 g/day than 2.4 g/day (resolution, 19 vs 29 days; 
P = 0.020).27 Endoscopic healing rates (improvement in or 
resolution of mucosal damage seen at endoscopy) occur 
in 30%–80% of patients treated with mesalamine within 
6 to 8 weeks.28 In a pooled retrospective analysis of the 
ASCEND 1 and 2 data in UC patients receiving delayed 
release oral mesalamine (Asacol) at week 6, 80% on 4.8 g/day 
  compared to 68% on 2.4 g/day (P = 0.012) achieved endo-
scopic   healing.29 A post-hoc analysis of trial data of   topical 
mesalamine suspension concluded that this mesalamine 
delivery method also led to earlier symptom improvement and 
endoscopic mucosal healing of distal colitis when compared 
to placebo or oral mesalamine alone.30
Oral steroids are generally reserved for patients who are 
refractory to oral 5-ASA in combination with topical therapy 
and have troublesome symptoms that require quick resolution. 
Corticosteroids are not efficacious in maintenance treatment 
and are not recommended for long-term treatment.31 Patients 
who cannot be weaned off corticosteroids may need the 
introduction of azathioprine, 6-mercaptopurine (6MP), or 
infliximab as a steroid-sparing agent to avoid long-term 
corticosteroid use. Azathioprine and 6-MP are effective in 
maintaining remission in patients with moderate-to-severe 
disease, but they are not suitable for the induction of remis-
sion due to the prolonged time to take effect (8–12 weeks).3 
The role of methotrexate in UC is still unclear and is a mat-
ter for ongoing study.32 Infliximab is an effective treatment 
for patients with moderate-to-severe disease, those who are 
  steroid-refractory or steroid dependent despite adequate doses 
of a thiopurine, or who are intolerant of these medications 
due to side effects.33 Selective leukocytapheresis therapy 
has also been shown to be effective in treatment of some 
moderately severe UC patients who do not respond to 5-ASA 
or corticosteroids.34 Severe active UC can be treated with 
intravenous steroids, cyclosporine, or infliximab, which is a 
form of rescue therapy and acts as a bridge to maintenance 
therapy with thiopurines or scheduled infliximab therapy.35
In addition to pharmacological management, health 
maintenance is important in patients with UC.36 It is recom-
mended that patients get routine vaccinations, such as yearly 
influenza, pneumococcal every 5 years, tetanus booster every 
10 years, complete hepatitis A and B vaccinations, varicella 
or zoster (contraindicated on biologic therapy), and human 
papillomavirus for females. Periodic blood test monitoring 
is also important, depending on the maintenance therapy; 
moreover, full blood count, liver function, and renal function 
should be monitored. Annual screening of vitamin D levels 
should be considered in patients exposed to corticosteroids, 
and urinalysis should be considered for early screening of 
nephritis. Patients with long-standing inflammatory   disease 
(pancolitis of 8–10 years and left-sided colitis of over 
10 years) should have surveillance colonoscopy every 1 to 
2 years once there is no evidence of dysplasia on serial 
  biopsies. Bone mineral density, yearly dermatological exami-
nations (especially on immunomodulators and biologics) as 
well as a mammogram and pap smears for women should 
be considered. Patients should also take calcium 1200 g per 
day and vitamin D 400–800 IU per day.
Focus on MMX® mesalamine
Since the mode of action of mesalamine in UC is thought to 
be a topical effect on the colonic mucosa, all oral mesalamine 
formulations for UC are designed to deliver 5-ASA to the 
colon. Unbound 5-ASA ingested orally is rapidly absorbed in 
the small intestine, so encapsulation in pH-sensitive coatings 
or with cellulose granules are necessary to prevent premature 
small bowel absorption of mesalamine. The pharmacology 
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of MMX mesalamine is very similar to other mesalamine 
  formulations, and differs only in the duration and timing 
of colonic release of unbound 5-ASA. MMX® mesalamine 
technology comprises hydrophilic and lipophilic excipients 
enclosed in a gastric-resistant, pH-dependent coating.37 
Eudragit-S (used in Lialda/Mezavant; Shire Pharmaceuticals) 
is a pH-sensitive polymer that disintegrates at a pH . 7, 
allowing the drug to be released in the terminal ileum or 
cecum.38 The additional lipophilic and hydrophilic matrices 
within the capsule are designed to allow slower diffusion of 
the drug through the colon. This delivery system allows a 
once-daily administration of high-concentration tablets.39
Pharmacokinetics
The results of plasma pharmacokinetics (pK) analyses and 
mucosal concentrations of delayed-release formulations of 
5-ASA have shown high interindividual variability in healthy 
volunteers and patients with active and inactive UC.40,41 
  Following administration of a single dose of either a delayed-
release or an azo-bonded formulation, only approximately 20% 
of the 5-ASA is taken up systemically (assessed by analysis of 
5-ASA and its main metabolite, N-acetyl-5-  aminosalicylic acid 
[N-acetyl-5-ASA] in urine).42 Mesalamine and its metabolite 
are also secreted back into the colonic lumen following uptake 
by the colonic mucosa, reducing further the amount of 5-ASA 
that will progress to the plasma.43   Administration with food 
delays the first appearance of mesalamine in the plasma by 
2 hours compared with administration in the fasted state.44 
Variations in transit times and pH conditions in patients with 
UC could potentially affect how the drug is released and taken 
up by colonic mucosa.45
In a single and multiple dose pharmacokinetic study 
of Lialda, 2.4 g or 4.8 g was administered once daily with 
standard meals to 28 healthy volunteers per dosage group.44 
Plasma concentrations of mesalamine were detectable after 
4 hours and were maximal by 8 hours after the single dose. 
Steady state was achieved generally within 2 days after 
dosing. Mean area under the curve at steady state was only 
modestly greater (1.1- to 1.4-fold) than that predictable 
from single-dose pharmacokinetics (Table 1). Elimination 
of absorbed mesalamine is mainly via the renal route fol-
lowing metabolism to N-acetyl-5-ASA. Total (5-ASA and 
N-acetyl-5-ASA) urinary excretion of oral mesalamine over 
24 hours was 21.3%.46 In a study comparing Asacol and 
Lialda, both of which were dosed once daily, both drugs 
exhibited a similar pK profile in healthy volunteers.4 A sys-
tematic review of the pharmacokinetic profiles of the different 
5-ASA formulations found that systemic 5-ASA absorption 
was comparable for the pH-dependent, controlled release, 
and prodrug formulations.47
Pharmacodynamics
5-ASA is believed to exert a direct effect on the colonic 
mucosa through a number of different, but not mutually 
exclusive, anti-inflammatory mechanisms of action.48 
5-ASA acts as a synthetic agonist to the peroxisome 
  proliferator-activated receptor-γ (PPAR-γ), which is known 
to be involved in UC inflammation.49 It also has been shown 
to inhibit prostaglandin synthesis (via inhibition of cyclooxy-
genase), chemotactic leukotriene synthesis (via inhibition of 
lipoxygenase),50 interleukin-1 (IL-1) synthesis,51 nuclear 
factor kappa B (NF-κB) activation by tumor necrosis fac-
tor (TNF) alpha52 and IL-1,53 and apoptosis induced by 
oxidative stress.54 No specific studies on the mechanism of 
action of MMX mesalamine have been published because 
the anti-inflammatory effects of mesalamine are assumed to 
be ubiquitous.
Clinical efficacy of MMX mesalamine
Several randomized placebo-controlled trials have investi-
gated the safety and efficacy of MMX mesalamine compared 
to placebo.25,26,39,55–59 The efficacy of MMX mesalamine 
in inducing remission in active UC was demonstrated in 
two randomized, double-blind placebo-controlled trials39,55 
(Table 2). Kamm et al randomized 343 patients with active 
mild-moderate UC to receive Lialda (2.4 g/day or 4.8 g/day), 
Asacol (2.4 g/day), or placebo.39 After 8 weeks, 40.5% of the 
2.4 g/day (P = 0.01) and 41.2% of the 4.8 g/day (P = 0.007) 
achieved clinical and endoscopic remission, compared 
to 22.1% in the placebo arm. No comparative statistical 
analyses between the Asacol and MMX mesalamine group 
were reported. They also showed that MMX mesalamine 
Table 1 Mean (±SD) pK parameters for mesalamine following 
single dose and steady state administration of MMX mesalamine 
under fasting or postprandial status
Dosage N Cmax  
(ng/mL)
Median  
Tmax (hours)
AUC0–∞ 
(ng h mL)
t½  
(hours)
2.4 g40,a 48 1595  
(±1484)
12 (4–31) 21,084  
(±13185)
7.05  
(±5.54)
4.8 g40,a 48 2154  
(±1140)
12 (4–34) 44775  
(±30,302)
7.25  
(±8.32)
2.4 g42,b 37 1553c 
(857–2812)
13,556c  
(7616–24,128)
10.2c  
(5.8–19.9)
Notes: asingle dose administration (fasting); bsteady state administration (postpran-
dial); csquare geometric means (95% confidence intervals).
Abbreviations: SD, standard deviation; AUC, area under the plasma concentration- 
time curve; Cmax, maximum plasma concentration; t½, elimination half-life; Tmax, 
time to Cmax.
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at a higher dose (4.8 g once daily) was associated with 
endoscopic improvement compared to placebo (77% vs 
41%), MMX mesalamine at a dose of 2.4 g once daily, and 
delayed release mesalamine was not statistically significant 
compared to placebo. However both low and high doses of 
MMX mesalamine were associated with improved induc-
tion of endoscopic remission (69% and 76%) compared to 
placebo (46%). Similarly, Lichtenstein et al showed that 
MMX mesalamine (2.4 g/day or 4.8 g/day) was superior 
to placebo in inducing remission in patients with mild-to-
moderate UC.55 There was no significant difference in terms 
of the clinical and endoscopic remission rate between the 
MMX mesalamine 1.2 g twice daily and 4.8 g once daily 
groups (odds ratio [OR], 1.25; 95% CI: 0.66–2.36). Median 
time to achieve initial clinical remission was significantly 
shorter in the MMX mesalamine 1.2 g twice daily (43 days) 
or 4.8 g once daily (44 days) groups than in the placebo 
group (which was not achieved).55 Both studies excluded 
patients with ulcerative proctitis (inflammation to .15 cm 
from the anus).
In a pooled analysis of the above studies, MMX mesala-
mine was found effective in active UC regardless of dis-
ease extent, disease severity, sex, and previous low-dose 
5-ASA therapy.56 In an induction extension study by Kamm 
et al, patients who did not achieve the primary endpoint 
of clinical and endoscopic remission in the 8-week Phase 
III trials (n = 304) were eligible for enrolment in the non-
comparative extension study in which all patients received 
MMX mesalamine 4.8 g/day, given as 2.4 g twice daily for 
8 weeks.58 This extension treatment was effective in inducing 
remission in 59.5% of patients previously not in remission. 
Remission rates were similar irrespective of prior treatment in 
the acute Phase III studies (MMX 2.4 g/day, MMX 4.8 g/day, 
Asacol 0.8 g/day, or placebo).58
Maintenance of remission
The efficacy of MMX mesalamine as maintenance therapy 
in UC has been assessed in two 12-month, randomized, 
double-blind25 or open-label,59 multicenter Phase III trials 
and a 12-month noncomparative, multicenter Phase IV trial26 
(Table 3). The efficacy of MMX mesalamine was shown in 
a trial in which patients in clinical and endoscopic remission 
(after being treated with MMX mesalamine) were randomly 
assigned to MMX mesalamine 1.2 g twice daily or 2.4 g every 
day.59 At 1 year, the two regimens were associated with a 
similar rate of clinical and endoscopic remission (64% vs 
69%). A study comparing Lialda 2.4 g daily and Asacol 
2.4 g daily found no significant difference between the two 
drugs in maintaining clinical remission (68% and 65.9%, 
respectively).25 Kane et al showed that MMX mesalamine 
2.4 g/day, maintained disease quiescence in 76.5% of patients 
at 6 months (primary endpoint) and 64.4% at 12 months.26 
As a secondary analysis, clinical recurrence was observed 
in 20.6% of patients who were $80% adherent and 36.1% 
of patients with ,80% adherence (P = 0.05).
Data on studies of MMX mesalamine in endoscopic main-
tenance of remission is sparse. In the maintenance of remis-
sion studies by Kamm et al59 and Prantera et al,25 no major 
difference was noted between once daily and twice daily dos-
ing of MMX mesalamine or between MMX mesalamine and a 
delayed release mesalamine. A recent study by D’Haens et al 
showed that once daily dosing of MMX mesalamine at 2.4 g 
Table 2 Clinical efficacy of MMX mesalamine (MES) in induction (8 weeks) of remission in patients with mild to moderate 
ulcerative colitis
Study N Doses Clinical and endoscopic  
remission (%) (OR, 95% CI)
Failure  
rates (%)
Kamm et al39 84 MMX mesalamine 2.4 g daily 40.5** (2.40; 1.23–4.69) 21.4***
85 MMX mesalamine 4.8 g daily 41.2** (2.47; 1.15–5.30) 20.0***
86 Asacola 800 mg three times daily 32.6 (1.70; 0.86–3.36) 27.9**
86 Placebo 22.1 47.7
Lichtenstein et al56 88 MMX mesalamine 1.2 g twice daily 34.1*** (3.48; 1.44–8.41) 28.4***
85 MES 4.8 g daily 29.2** (2.78; 1.27–6.06) 24.7***
89 Placebo 12.9 54.1
Kamm et al58,b 197 MMX mesalamine 2.4 g twice daily  
(No response to MMX mesalamine previously)
59.5 _
107 MMX mesalamine 2.4 g twice daily  
(Placebo previously)
57 _
Notes: *P , 0.05; **P , 0.01; ***P , 0.001 vs placebo. aIncluded as an internal reference arm; no comparative statistical analyses with the mesalamine treatment arms 
were reported; bpatients who did not achieve the primary endpoint of clinical and endoscopic remission in the 8-week Phase III trials35,51 were eligible for enrolment in the 
noncomparative extension study (4.8 g MMX mesalamine for 8 weeks).54
Abbreviation: OR, odds ratio.
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was not inferior to twice daily dosing with delayed release 
mesalamine at 1.6 g/day for maintenance of endoscopic remis-
sion in patients with UC (83.7% vs 81.5%).60
Safety of MMX mesalamine
Newer 5-ASA preparations, such as MMX mesalamine, were 
intended to avoid the adverse effects of sulfasalazine while 
maintaining its therapeutic benefits. As class of drug, mesala-
mine has been shown to have an excellent safety profile and is 
well tolerated by patients.61 Examples of the unwanted effects 
of mesalamine reported include nausea, vomiting, dyspepsia, 
malaise, headache, abdominal pain, and rash.61 A paradoxical 
worsening of diarrhea has been attributed to mesalamine, 
especially early in therapy.62 Less common adverse effects 
include blood dyscrasias, pancreatitis, oligospermia (which 
is reversible upon discontinuation of the drug), drug-induced 
liver injury (DILI), and nephrotoxicity.63–65 To compare the 
short-term adverse events among the 5-ASA agents (mesala-
mine, olsalazine, and balsalazide), Loftus et al performed a 
meta-analysis of 46 randomized trials for mild-to-moderate 
UC.66 The study concluded that all three 5-ASA formulations 
produced similar adverse effects in the short term. Patients on 
mesalamine experience fewer adverse events or withdrawals 
due to serious side effects compared to those on sulfasalazine. 
The majority of treatment-emergent adverse events were mild 
to moderate in severity and most commonly gastrointestinal 
in nature.66
Renal damage occurring due to 5-ASA-based treatment of 
inflammatory bowel disease also appears to be rare. Adverse 
reactions consist of hypersensitivity reactions and, in the case 
of mesalamine, chronic interstitial nephritis. Fifty percent of 
reported cases of mesalamine-induced interstitial nephritis 
present within 1 year of treatment initiation, but the reported 
time range for presentation is wide at 3 months to 5 years.67 
The review of reported cases by World et al showed that 85% 
of cases of interstitial nephritis detected within 10 months 
of mesalamine therapy initiation responded completely to 
drug withdrawal with restoration of normal renal function.67 
Unfortunately, interstitial nephritis is difficult to detect early 
by urinalysis, and currently there are no screening methods 
other than monitoring serum creatinine. Regular monitor-
ing of renal function is recommended in patients receiving 
MMX mesalamine.36
Because mesalamine inhibits thiopurine methyltrans-
ferase, which metabolizes thiopurine-containing drugs, 
there is an increased potential for blood disorders when 
mesalamine is taken with concomitant azathioprine or mer-
captopurine.68 Mesalamine may decrease anticoagulant activ-
ity when coadministered with coumarin-type anticoagulants 
(eg, warfarin), and close monitoring of the prothrombin time 
is recommended.69
MMX mesalamine specifically is generally well toler-
ated, with no clinically significant differences in tolerability 
compared with placebo39,55 or Asacol.25,39 No dose-dependent 
relationship to adverse events was noted between MMX 
mesalamine dosage groups in the 8-week induction trials.39,55 
Treatment-related adverse events were reported in 14.1% 
of MMX mesalamine 2.4 g/day recipients, 14.5% of MMX 
mesalamine 4.8 g/day recipients, and 14.0% of placebo 
recipients in the two 8-week Phase III trials,57 in 8.0% of 
MMX mesalamine 2.4 g/day recipients, 9.5% of Asacol 
2.4 g/day recipients in the 12-month European trial,25 and 
in 11.5% of MMX mesalamine recipients as reported in a 
Phase IV study published recently.26
Limited data are available on the use of MMX mesala-
mine in pregnant patients. A meta-analysis of the use of 
mesalamine or mesalamine-containing drugs in pregnant 
women with IBD did not show a statistically significant 
difference compared with no medication in the incidence of 
congenital malformations, stillbirth, spontaneous abortion, 
preterm delivery, or low birth weight.70 However, MMX 
mesalamine should only be used in pregnant patients if the 
benefits clearly outweigh the risks.44
MMX mesalamine in clinical practice
Quality of life
Past studies with UC patients indicated that disease activity 
strongly predicts health-related quality of life (HRQoL).71,72 
Table 3 Clinical efficacy of MMX mesalamine in maintenance of remission (12 months) in patients with mild to moderate ulcerative colitis
Study N Doses Clinical and endoscopic  
remission (%)
Relapse rates  
at 12 months (%)
Kamm et al59 232 MMX mesalamine 1.2 g twice daily 68.5 6.8
219 MMX mesalamine 2.4 g twice daily 64.4 11.1
Prantera et al25 162 MMX mesalamine 2.4 g once daily 60.9a 15.0
156 Asacol 2.4 g once daily 61.7a 29.9
Kane et al26 167 MMX mesalamine 2.4 g once daily _ 35.6a
Note: aPrimary endpoint.
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The first study to assess MMX mesalamine in changes to 
  disease specific HRQoL reported that following 8 weeks of 
treatment with MMX mesalamine 2.4–4.8 g/day, patients with 
active mild-to-moderate UC showed significant improvement 
in all aspects of disease-specific HRQoL measured by the 
Short Inflammatory Bowel Disease Questionnaire (SIBDQ).73 
This quality-of-life level was maintained by quiescent UC 
patients in the course of year-long continuous once-daily 
MMX mesalamine 2.4 g/day treatment.73 The improvements 
in HRQoL corresponded to improvements in disease activity 
in the active group more so than the quiescent group.
Adherence
Up to 40% of patients with UC fail to comply with 5-ASA 
therapy.74,75 In patients who received non-MMX or MMX 
formulations of mesalamine, nonadherence to treatment was 
associated with a higher likelihood of disease recurrence, 
a higher financial cost of health care management, and a 
reduced level of protection against the development of CRC 
than adherence to treatment.26,76–78 A variety of barriers to 
adherence have been reported by patients, including lifestyle, 
risk of side effects, and financial factors.79,80 A once-daily dose 
of mesalamine has been shown as effective as twice daily, 
with improved patient compliance in those with reduced pill 
burden.81 However, a meta-analysis by Ford et al comparing 
once-daily dosing with mesalamine with conventional dosing 
schedules showed no significant benefit of once daily over 
multiple doses in risk of nonadherence (relative risk [RR], 
0.87; 95% CI: 0.46–1.66).20 Although compliance was .85% 
in all three 12-month maintenance trials,25,26,58 the impact of 
once-daily dosing on long-term treatment adherence in the 
community remains to be seen. Patients receiving once-daily 
MMX mesalamine had significantly higher persistency after 
1 year of treatment than patients receiving other oral 5-ASA 
therapies, based on pharmacy refills.82
Drug costs
The wholesale cost of MMX mesalamine is US$726 for 
a pack of 120 tablets.83 The cost-effectiveness of MMX 
mesalamine relative to Asacol as remission induction and 
maintenance therapy in adult patients with mild-to-moderate 
UC was performed from a UK health care payer’s perspective. 
It concluded that MMX mesalamine was associated with an 
incremental cost per patient but with significant increase in 
remission times, fewer hospitalizations, and fewer surgi-
cal events per patient.84 Further comparative cost-effective 
studies of mesalamine agents and doses are required to 
confirm this finding in other settings.
Chemoprophylaxis of CRC
The cumulative life time risk of developing CRC in patients 
with UC has been reported in historical cohorts to be as high 
as 10%–20%.85 More recent population-based data have 
shown that the risk of CRC is actually closer to 1.3%–1.6% 
after 14–15 years in IBD patients.86,87 A meta-analysis by Jess 
et al showed that in CRC, risk was higher in UC patients with 
a pooled SIR of 2.4 (95% CI: 2.1–2.7).88 Male sex, young age 
of diagnosis, and extensive colitis were particular risk factors. 
Case control studies of patients with colon cancer and UC 
have reported conflicting data on the impact of 5-ASA on the 
risk of CRC.89–91 A prospective RCT of 5-ASA in prevention 
of polyps in adults with a history of polyps did not show 
a chemoprotective effect of 5-ASA.92 A meta-analysis of 
nine observational studies involving 1932 patients reported 
a protective association between 5-ASA use and CRC (OR, 
0.51; 95% CI: 0.37–0.69) or a combined endpoint of CRC 
and dysplasia (OR 0.51; 95% CI: 0.38–0.69), which equates 
to a 49% reduction in the risk of CRC or CRC/dysplasia with 
regular 5-ASA use.93 The reduced risk was maintained by 
regular use of at least 1.2 g of mesalamine daily.   Compliance 
with prescribed 5-ASA therapy can influence the risk of 
CRC. A nested case-control study involving 18,969 patients 
with IBD in the UK General Practice Research Database 
(1987–2001) showed that regular 5-ASA users (defined as six 
prescriptions in the previous 12 months) had a significantly 
reduced risk of CRC compared with irregular 5-ASA users 
(adjusted OR, 0.60; 95% CI: 0.38–0.96).76 No specific pub-
lished studies have examined the role of MMX mesalamine 
in CRC prophylaxis.
A recent publication suggested that the overall risk of 
CRC among patients with UC was comparable to that of 
the general population (RR, 1.07; 95% CI: 0.95–1.21) and 
that the risk for CRC in UC patients is on a decline.87 For 
patients with UC, the overall RR for CRC decreased from 
1.34 (95% CI: 1.13–1.58) in 1987 to 1988 to 0.57 (95% CI: 
0.41–0.80) in 1999 to 2008. The declining risk for CRC 
from 1979 to 2008 might result from improved therapies 
for patients with IBD.
Conclusion
Mesalamine is an effective first-line agent for the induction 
and maintenance of remission in patients with mild-to-
moderate UC when administered orally, rectally, or both. 
For patients with more severe disease, other agents such as 
steroids or infliximab are required. There may be additional 
benefits from mesalamine in chemoprophylaxis against 
colon cancer, but there is conflicting data on this subject. 
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Adherence to treatment schedules with mesalamine remains 
an issue in practice. MMX mesalamine provides a higher 
per-pill dose of mesalamine than other mesalamine formu-
lations, allowing for once-daily dosing. The reduced pill 
burden may improve patient adherence in clinical practice, 
although this will require further study to confirm. Its efficacy 
and safety profile is similar to other mesalamine formula-
tions. As the patent for the pioneer mesalamine formula-
tion (Asacol; Warner Chilcott Company, Dublin, Ireland) 
approaches patent expiry (July, 2013), it is unclear how the 
arrival of generic mesalamine formulations will affect MMX 
mesalamine’s share of the US market and whether third-party 
payers (insurers and governments) will tier access to MMX 
mesalamine in the face of cheaper mesalamine options.
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